An update from AIM Vaccine Co., Ltd. Class H ( (HK:6660) ) is now available.
AIM Vaccine Co., Ltd. has announced its 2024 Annual General Meeting (AGM) to be held on May 20, 2025, in Shanghai. The AGM will address several key resolutions, including the approval of the 2024 annual report, financial statements, profit distribution plan, and the re-appointment of Ernst & Young as the auditor for 2025. Special resolutions will also be considered, granting the Board mandates to issue new shares and repurchase H shares, as well as proposed amendments to the Articles of Association. These resolutions are pivotal for the company’s strategic direction and governance, potentially impacting its market operations and shareholder value.
More about AIM Vaccine Co., Ltd. Class H
AIM Vaccine Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, operating within the biotechnology industry. The company focuses on the development, production, and distribution of vaccines, serving a critical role in public health by providing immunization solutions.
YTD Price Performance: -44.79%
Average Trading Volume: 6,162,144
Technical Sentiment Signal: Buy
For detailed information about 6660 stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
- “Be the Leader You’ve Been Complaining For!” Paramount Stock (NASDAQ:PARA) Dips as Paramount Pulls Out of Politics
- Don’t “Get Rid of All Your Engine Designers”: Ford Stock (NYSE:F) Dips as it Brings Back a Big Name in Internal Combustion
- “Advanced Silicon Wafer Tests” Start; Intel Stock (NASDAQ:INTC) Slips